Boothbay Fund Management’s Valion Bio VBIO Stock Holding History

Boothbay Fund Management’s Portfolio VBIO Stock Details VBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1	Closed	-$3.62K	–	2080
2023 Q2	$3.62K	Hold	1	–	–	﹤0.01%	1731
2023 Q1	$4.52K	Buy	+1	New	+$17.5K	﹤0.01%	2080

Other funds holding VBIO

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Boothbay Fund Management's VBIO Position: Q3 2023 in Review

Boothbay Fund Management sold out of Valion Bio (VBIO) in Q3 2023, closing a stake of 1 share — an estimated $3.62K sold.

Boothbay Fund Management first reported a position in VBIO in Q1 2023 and held it in 2 quarters. The position peaked at $4.52K in Q1 2023. 3 funds tracked by Wall St. Rank hold VBIO as of Q3 2023.

Boothbay Fund Management reported no remaining Valion Bio position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 1 Valion Bio share in Q3 2023, an estimated $3.62K.
Boothbay Fund Management first reported a position in Valion Bio in Q1 2023 and held it in 2 quarters.
Boothbay Fund Management's Valion Bio position peaked at $4.52K in Q1 2023.
3 funds tracked by Wall St. Rank held Valion Bio as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.